Kazuo Fujihara

Koriyama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 252 publications

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.

Journal: Neurology and therapy

Published: March 27, 2026

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 26, 2026

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 24, 2026

Neuromyelitis optica spectrum disorders.

Neuromyelitis optica spectrum disorders.

Journal: Therapeutic advances in neurological disorders

Published: February 14, 2026

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 11, 2026

Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Journal: International journal of molecular sciences

Published: December 14, 2025

Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS.

Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS.

Journal: Acta neuropathologica

Published: October 22, 2025

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 06, 2025

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 31, 2025

Childhood and Adolescent Environmental Risk Factors for Multiple Sclerosis: A Systematic Review With Meta-Analysis.

Childhood and Adolescent Environmental Risk Factors for Multiple Sclerosis: A Systematic Review With Meta-Analysis.

Journal: European journal of neurology

Published: July 31, 2025

Progress in the management of pregnancy in patients with neuromyelitis optica spectrum disorder.

Progress in the management of pregnancy in patients with neuromyelitis optica spectrum disorder.

Journal: Therapeutic advances in neurological disorders

Published: June 21, 2025

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Journal: Neurology and therapy

Published: April 18, 2025

Showing 1-12 of 252

Last Updated: 09/26/2026